ATLASJazz Pharmaceuticals (JAZZ) earnings date: Nov 2, 2026
Jazz Pharmaceuticals (JAZZ) reports earnings for the quarter ended Sep 30, 2026 on Mon, Nov 2, 2026, after the close. Analysts expect EPS of -$5.18.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on JAZZ
| Last price | $215.98 (+3.9%) |
|---|---|
| Normal 1-day range (±1σ) | ±1.8% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Jazz Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Jazz Pharmaceuticals reports on Nov 2, 2026. One email the day before, with ATLAS’s read on Jazz Pharmaceuticals. You can switch it off at any time.
Alert me before JAZZ reportsFree to start. Creating an account takes under a minute.
JAZZ earnings at a glance
| Next report (confirmed) | Mon, Nov 2, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$5.18 |
| Last report | Aug 3, 2026 · Miss |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | +13.9% |
| Average move around a report | ±6.4% (last 5) |
| Sector | Healthcare · Biotechnology |
Jazz Pharmaceuticals earnings history: last 5 reports
Jazz Pharmaceuticals last reported on Aug 3, 2026: EPS of $5.71 against an estimate of $6.18 (-7.6% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 3, 2026 | $6.18 | $5.71 | -7.6% | Miss | +3.5% |
| May 5, 2026 | $4.66 | $6.34 | +36.1% | Beat | +9.9% |
| Feb 24, 2026 | $6.51 | $6.64 | +2.0% | In line | +13.6% |
| Jan 28, 2026 | $1.03 | $1.03 | 0.0% | In line | -2.3% |
| Nov 5, 2025 | $5.85 | $8.13 | +39.0% | Beat | -2.7% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for JAZZ
See the fair value, the probability range and the earnings history of Jazz Pharmaceuticals on its ATLAS page.
Jazz Pharmaceuticals (JAZZ) stock analysisPlans from €3.99 a month.
Jazz Pharmaceuticals earnings: frequently asked questions
When does Jazz Pharmaceuticals (JAZZ) report earnings?
Jazz Pharmaceuticals is scheduled to report on Monday, November 2, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for JAZZ?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$5.18 per share (USD). Estimates can change before the report.
How often does JAZZ beat earnings estimates?
Of its last 5 reports with a recorded result, Jazz Pharmaceuticals beat the EPS estimate 2 times; the average surprise was +13.9%. Past results do not predict the next one.
How much does JAZZ move around earnings?
Over its last 5 reports the stock moved an average of 6.4% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did Jazz Pharmaceuticals beat earnings estimates last quarter?
Jazz Pharmaceuticals last reported on Aug 3, 2026: EPS of $5.71 against an estimate of $6.18 (-7.6% surprise), a miss.
How much does JAZZ usually move in a day?
On a normal trading day the ATLAS model puts JAZZ’s one-day range at about ±1.8%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Mon, Nov 2, 2026
Educational information, not investment advice. Disclaimer